Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 6/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | LIG1 | P18858 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1587492 | 0.86 | HPGD (0.46) | HPGDALDH1A1TDP1RAB9ANPC1 | |
| SCHEMBL14625174 | 0.86 | F2 (0.41) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL1588149 | 0.83 | ALDH1A1 (0.42) | ALDH1A1TDP1MAPTPOLBKMT2A | |
| SCHEMBL14625177 | 0.83 | KDM4E (0.41) | HPGDALDH1A1TDP1RAB9ANPC1 | |
| SCHEMBL12529804 | 0.83 | HPGD (0.44) | HPGDALDH1A1TDP1RAB9ANPC1 | |
| SCHEMBL11977472 | 0.80 | YEATS4 (0.42) | DAOHPGDRAB9ANPC1KMT2A | |
| SCHEMBL1588044 | 0.80 | NPSR1 (0.40) | HPGDALDH1A1MAPTPOLB | |
| SCHEMBL31468333 | 0.73 | PGR (0.47) | ALDH1A1TDP1RAB9ANPC1MAPT | |
| Alcohol SCHEMBL28943550 | 0.72 | DAO (0.60) | DAOPKMLIG1HPGDALDH1A1 | |
| SCHEMBL10161072 | 0.71 | DAO (0.54) | DAOPKMLIG1HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968542-B2 | Thiophene compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-06-28 | — | — | US | disclosed |
| US-20090118500-A1 | THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-1904472-A1 | THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007010954-A1 | THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118500-A1 | THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | TEK, MPL, THPO | DAO 2712/4885PKM 1966/4885LIG1 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.